Do analysts prefer VYNE or INM?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score VYNE Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 InMed Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts prefer INM or ZIVO?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score InMed Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 ZIVO Bioscience 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Do analysts recommend INM or CYCN?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score InMed Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Cyclerion Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts rate LPCN or INM?

Lipocine presently has a consensus target price of $15.00, suggesting a potential upside of 616.67%. Given Lipocine's stronger consensus rating and higher possible upside, research analysts plainly believe Lipocine is more favorable than InMed Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lipocine 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 InMed Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts rate INM or SCNX?

Scienture has a consensus price target of $1.50, suggesting a potential upside of 244.83%. Given Scienture's stronger consensus rating and higher possible upside, analysts plainly believe Scienture is more favorable than InMed Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score InMed Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Scienture 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

InMed Pharmaceuticals (INM) Competitors

$1.46 +0.04 (+2.45%)

As of 10:11 AM Eastern

Compare

INM vs. VYNE, ZIVO, CYCN, LPCN, and SCNX

Should you buy InMed Pharmaceuticals stock or one of its competitors? InMed Pharmaceuticals's main competitors and comparable companies include VYNE Therapeutics (VYNE), ZIVO Bioscience (ZIVO), Cyclerion Therapeutics (CYCN), Lipocine (LPCN), and Scienture (SCNX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does InMed Pharmaceuticals compare to VYNE Therapeutics?

VYNE Therapeutics (NASDAQ:VYNE) and InMed Pharmaceuticals (NASDAQ:INM) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, earnings, analyst recommendations, institutional ownership, risk, media sentiment, profitability and valuation.

InMed Pharmaceuticals has higher revenue and earnings than VYNE Therapeutics. VYNE Therapeutics is trading at a lower price-to-earnings ratio than InMed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
VYNE Therapeutics	$570K	33.29	-$26.48M	-$0.38	N/A
InMed Pharmaceuticals	$4.94M	0.98	-$8.16M	-$2.89	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
VYNE Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
InMed Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

VYNE Therapeutics has a beta of 2, meaning that its stock price is 100% more volatile than the broader market. Comparatively, InMed Pharmaceuticals has a beta of 0.96, meaning that its stock price is 4% less volatile than the broader market.

83.8% of VYNE Therapeutics shares are owned by institutional investors. Comparatively, 20.1% of InMed Pharmaceuticals shares are owned by institutional investors. 3.0% of VYNE Therapeutics shares are owned by company insiders. Comparatively, 0.9% of InMed Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

InMed Pharmaceuticals has a net margin of -132.87% compared to VYNE Therapeutics' net margin of -4,726.21%. VYNE Therapeutics' return on equity of -70.42% beat InMed Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
VYNE Therapeutics	-4,726.21%	-70.42%	-63.46%
InMed Pharmaceuticals	-132.87%	-80.85%	-68.11%

In the previous week, VYNE Therapeutics and VYNE Therapeutics both had 1 articles in the media. InMed Pharmaceuticals' average media sentiment score of 1.87 beat VYNE Therapeutics' score of -3.00 indicating that InMed Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
VYNE Therapeutics	Very Negative
InMed Pharmaceuticals	Very Positive

Summary

VYNE Therapeutics beats InMed Pharmaceuticals on 7 of the 12 factors compared between the two stocks.

How does InMed Pharmaceuticals compare to ZIVO Bioscience?

InMed Pharmaceuticals (NASDAQ:INM) and ZIVO Bioscience (NASDAQ:ZIVO) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, earnings, dividends, profitability, institutional ownership, risk and valuation.

ZIVO Bioscience has lower revenue, but higher earnings than InMed Pharmaceuticals. ZIVO Bioscience is trading at a lower price-to-earnings ratio than InMed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InMed Pharmaceuticals	$4.94M	0.98	-$8.16M	-$2.89	N/A
ZIVO Bioscience	$15.85K	1,141.13	-$7.78M	-$1.71	N/A

InMed Pharmaceuticals has a beta of 0.96, indicating that its stock price is 4% less volatile than the broader market. Comparatively, ZIVO Bioscience has a beta of 0.14, indicating that its stock price is 86% less volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InMed Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
ZIVO Bioscience	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

20.1% of InMed Pharmaceuticals shares are held by institutional investors. Comparatively, 12.8% of ZIVO Bioscience shares are held by institutional investors. 0.9% of InMed Pharmaceuticals shares are held by company insiders. Comparatively, 48.9% of ZIVO Bioscience shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

ZIVO Bioscience has a net margin of 0.00% compared to InMed Pharmaceuticals' net margin of -132.87%. ZIVO Bioscience's return on equity of 0.00% beat InMed Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
InMed Pharmaceuticals	-132.87%	-80.85%	-68.11%
ZIVO Bioscience	N/A	N/A	-2,240.92%

In the previous week, InMed Pharmaceuticals had 1 more articles in the media than ZIVO Bioscience. MarketBeat recorded 1 mentions for InMed Pharmaceuticals and 0 mentions for ZIVO Bioscience. InMed Pharmaceuticals' average media sentiment score of 1.87 beat ZIVO Bioscience's score of 0.00 indicating that InMed Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
InMed Pharmaceuticals	Very Positive
ZIVO Bioscience	Neutral

Summary

InMed Pharmaceuticals beats ZIVO Bioscience on 8 of the 14 factors compared between the two stocks.

How does InMed Pharmaceuticals compare to Cyclerion Therapeutics?

InMed Pharmaceuticals (NASDAQ:INM) and Cyclerion Therapeutics (NASDAQ:CYCN) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, media sentiment, dividends, valuation, profitability, institutional ownership, earnings and analyst recommendations.

In the previous week, InMed Pharmaceuticals and InMed Pharmaceuticals both had 1 articles in the media. Cyclerion Therapeutics' average media sentiment score of 1.89 beat InMed Pharmaceuticals' score of 1.87 indicating that Cyclerion Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
InMed Pharmaceuticals	Very Positive
Cyclerion Therapeutics	Very Positive

InMed Pharmaceuticals has a net margin of -132.87% compared to Cyclerion Therapeutics' net margin of -170.11%. InMed Pharmaceuticals' return on equity of -80.85% beat Cyclerion Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
InMed Pharmaceuticals	-132.87%	-80.85%	-68.11%
Cyclerion Therapeutics	-170.11%	-87.96%	-74.86%

Cyclerion Therapeutics has lower revenue, but higher earnings than InMed Pharmaceuticals. Cyclerion Therapeutics is trading at a lower price-to-earnings ratio than InMed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InMed Pharmaceuticals	$4.94M	0.98	-$8.16M	-$2.89	N/A
Cyclerion Therapeutics	$2.07M	8.70	-$3.53M	-$1.66	N/A

InMed Pharmaceuticals has a beta of 0.96, meaning that its share price is 4% less volatile than the broader market. Comparatively, Cyclerion Therapeutics has a beta of 1.76, meaning that its share price is 76% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InMed Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Cyclerion Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

20.1% of InMed Pharmaceuticals shares are owned by institutional investors. Comparatively, 75.6% of Cyclerion Therapeutics shares are owned by institutional investors. 0.9% of InMed Pharmaceuticals shares are owned by insiders. Comparatively, 34.3% of Cyclerion Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Cyclerion Therapeutics beats InMed Pharmaceuticals on 7 of the 12 factors compared between the two stocks.

How does InMed Pharmaceuticals compare to Lipocine?

Lipocine (NASDAQ:LPCN) and InMed Pharmaceuticals (NASDAQ:INM) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, valuation, earnings, risk, dividends, analyst recommendations, profitability and media sentiment.

Lipocine has a beta of 0.46, suggesting that its share price is 54% less volatile than the broader market. Comparatively, InMed Pharmaceuticals has a beta of 0.96, suggesting that its share price is 4% less volatile than the broader market.

InMed Pharmaceuticals has higher revenue and earnings than Lipocine. Lipocine is trading at a lower price-to-earnings ratio than InMed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lipocine	$1.98M	8.71	-$9.63M	-$1.79	N/A
InMed Pharmaceuticals	$4.94M	0.98	-$8.16M	-$2.89	N/A

9.1% of Lipocine shares are owned by institutional investors. Comparatively, 20.1% of InMed Pharmaceuticals shares are owned by institutional investors. 4.7% of Lipocine shares are owned by insiders. Comparatively, 0.9% of InMed Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Lipocine had 1 more articles in the media than InMed Pharmaceuticals. MarketBeat recorded 2 mentions for Lipocine and 1 mentions for InMed Pharmaceuticals. InMed Pharmaceuticals' average media sentiment score of 1.87 beat Lipocine's score of 1.31 indicating that InMed Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Lipocine	Positive
InMed Pharmaceuticals	Very Positive

InMed Pharmaceuticals has a net margin of -132.87% compared to Lipocine's net margin of -755.39%. Lipocine's return on equity of -64.75% beat InMed Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lipocine	-755.39%	-64.75%	-57.62%
InMed Pharmaceuticals	-132.87%	-80.85%	-68.11%

Lipocine presently has a consensus target price of $15.00, suggesting a potential upside of 616.67%. Given Lipocine's stronger consensus rating and higher possible upside, research analysts plainly believe Lipocine is more favorable than InMed Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lipocine	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
InMed Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Lipocine beats InMed Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

How does InMed Pharmaceuticals compare to Scienture?

InMed Pharmaceuticals (NASDAQ:INM) and Scienture (NASDAQ:SCNX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, earnings, media sentiment, risk, dividends and valuation.

InMed Pharmaceuticals has higher revenue and earnings than Scienture. InMed Pharmaceuticals is trading at a lower price-to-earnings ratio than Scienture, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InMed Pharmaceuticals	$4.94M	0.98	-$8.16M	-$2.89	N/A
Scienture	$430K	41.10	-$41.51M	-$2.51	N/A

20.1% of InMed Pharmaceuticals shares are held by institutional investors. Comparatively, 5.7% of Scienture shares are held by institutional investors. 0.9% of InMed Pharmaceuticals shares are held by company insiders. Comparatively, 21.4% of Scienture shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Scienture had 7 more articles in the media than InMed Pharmaceuticals. MarketBeat recorded 8 mentions for Scienture and 1 mentions for InMed Pharmaceuticals. InMed Pharmaceuticals' average media sentiment score of 1.87 beat Scienture's score of 0.98 indicating that InMed Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
InMed Pharmaceuticals	Very Positive
Scienture	Positive

Scienture has a consensus price target of $1.50, suggesting a potential upside of 244.83%. Given Scienture's stronger consensus rating and higher possible upside, analysts plainly believe Scienture is more favorable than InMed Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InMed Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Scienture	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

InMed Pharmaceuticals has a beta of 0.96, indicating that its stock price is 4% less volatile than the broader market. Comparatively, Scienture has a beta of 3.26, indicating that its stock price is 226% more volatile than the broader market.

Scienture has a net margin of 0.00% compared to InMed Pharmaceuticals' net margin of -132.87%. Scienture's return on equity of -56.28% beat InMed Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
InMed Pharmaceuticals	-132.87%	-80.85%	-68.11%
Scienture	N/A	-56.28%	-44.76%

Summary

Scienture beats InMed Pharmaceuticals on 12 of the 16 factors compared between the two stocks.

Get InMed Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding INM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

INM vs. The Competition

Export

Metric	InMed Pharmaceuticals	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$4.85M	$11.68B	$6.96B	$13.10B
Dividend Yield	N/A	2.70%	2.58%	10.72%
P/E Ratio	-0.51	783.86	269.57	25.32
Price / Sales	0.98	745.72	595.01	100.00
Price / Cash	N/A	67.45	70.53	50.75
Price / Book	0.22	10.64	13.06	6.29
Net Income	-$8.16M	$2.77B	$3.45B	$347.70M
7 Day Performance	-0.34%	-0.25%	0.47%	0.89%
1 Month Performance	-6.09%	-0.12%	1.11%	0.85%
1 Year Performance	-37.39%	160.98%	66.38%	20.25%

InMed Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
INM InMed Pharmaceuticals	1.9479 of 5 stars	$1.47 +2.4%	N/A	-36.4%	$4.85M	$4.94M	N/A	10	Positive News
VYNE VYNE Therapeutics	0.2361 of 5 stars	$28.33 -0.8%	N/A	+63.0%	$18.98M	$570K	N/A	30	Negative News Earnings Report Gap Down High Trading Volume
ZIVO ZIVO Bioscience	N/A	$4.29 flat	N/A	-76.4%	$18.09M	$15.85K	N/A	10	Gap Down
CYCN Cyclerion Therapeutics	1.0171 of 5 stars	$3.81 +6.7%	N/A	+59.9%	$17.84M	$1.90M	N/A	30	Positive News
LPCN Lipocine	2.785 of 5 stars	$2.09 flat	$15.00 +617.7%	-31.6%	$17.22M	$1.98M	N/A	10	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:INM) was last updated on 8/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

InMed Pharmaceuticals (INM) Competitors

INM vs. VYNE, ZIVO, CYCN, LPCN, and SCNX

How does InMed Pharmaceuticals compare to VYNE Therapeutics?

Summary

How does InMed Pharmaceuticals compare to ZIVO Bioscience?

Summary

How does InMed Pharmaceuticals compare to Cyclerion Therapeutics?

Summary

How does InMed Pharmaceuticals compare to Lipocine?

Summary

How does InMed Pharmaceuticals compare to Scienture?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INM vs. The Competition

InMed Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

InMed Pharmaceuticals (INM) Competitors

INM vs. VYNE, ZIVO, CYCN, LPCN, and SCNX

How does InMed Pharmaceuticals compare to VYNE Therapeutics?

Which has stronger valuation & earnings, VYNE or INM?

Do analysts prefer VYNE or INM?

Which has more volatility & risk, VYNE or INM?

Do insiders and institutionals have more ownership in VYNE or INM?

Is VYNE or INM more profitable?

Does the media prefer VYNE or INM?

Summary

How does InMed Pharmaceuticals compare to ZIVO Bioscience?

Which has better earnings and valuation, INM or ZIVO?

Which has more risk & volatility, INM or ZIVO?

Do analysts prefer INM or ZIVO?

Do insiders and institutionals believe in INM or ZIVO?

Is INM or ZIVO more profitable?

Does the media refer more to INM or ZIVO?

Summary

How does InMed Pharmaceuticals compare to Cyclerion Therapeutics?

Does the media refer more to INM or CYCN?

Is INM or CYCN more profitable?

Which has preferable valuation and earnings, INM or CYCN?

Which has more volatility and risk, INM or CYCN?

Do analysts recommend INM or CYCN?

Do institutionals & insiders believe in INM or CYCN?

Summary

How does InMed Pharmaceuticals compare to Lipocine?

Which has more risk and volatility, LPCN or INM?

Which has higher valuation & earnings, LPCN or INM?

Do institutionals and insiders hold more shares of LPCN or INM?

Does the media prefer LPCN or INM?

Is LPCN or INM more profitable?

Do analysts rate LPCN or INM?

Summary

How does InMed Pharmaceuticals compare to Scienture?

Which has better earnings and valuation, INM or SCNX?

Do institutionals & insiders have more ownership in INM or SCNX?

Does the media refer more to INM or SCNX?

Do analysts rate INM or SCNX?

Which has more risk & volatility, INM or SCNX?

Is INM or SCNX more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INM vs. The Competition

InMed Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools